A 2020 update on liver transplant for hepatocellular carcinoma

被引:16
|
作者
Finotti, Michele [1 ]
Vitale, Alessandro [1 ]
Volk, Michael [2 ]
Cillo, Umberto [1 ]
机构
[1] Padova Univ Hosp, Dept Surg Oncol & Gastroenterol, Hepatobiliary Surg & Liver Transplantat Unit, Padua, Italy
[2] Loma Linda Univ Hlth, Div Gastroenterol & Hepatol, Loma Linda, CA USA
关键词
Benefit Models; downstaging; hepatocellular Carcinoma; liver transplantation; primary Liver Transplant; salvage Liver Transplant; transplant benefit; TO-LYMPHOCYTE RATIO; ALPHA-FETOPROTEIN; MICROVASCULAR INVASION; SURVIVAL BENEFIT; WAITING-LIST; TRANSARTERIAL CHEMOEMBOLIZATION; SALVAGE TRANSPLANTATION; LOCOREGIONAL THERAPY; SELECTION CRITERIA; MILAN CRITERIA;
D O I
10.1080/17474124.2020.1791704
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction Hepatocellular carcinoma is the most frequent liver tumor and is associated with chronic liver disease in 90% of cases. In selected cases, liver transplantation represents an effective therapy with excellent overall survival. Area covered Since the introduction of Milan criteria in 1996, numerous alternative selection systems to LT for HCC patients have been proposed. Debate remains about how best to select HCC patients for transplant and how to prioritize them on the waiting list. Expert opinion The selection of the best scoring system to propose in the context of LT for HCC is far to be identified. In this review, we analyze and categorize the various selection systems, assessing their roles in the different decisional phases.
引用
收藏
页码:885 / 900
页数:16
相关论文
共 50 条
  • [1] Liver Transplant and Hepatocellular Carcinoma
    Gish, Robert G.
    Clinical Advances in Hematology & Oncology, 2016, 14 (12) : 987 - 989
  • [2] Liver transplantation for hepatocellular carcinoma:an update
    Ali Zarrinpar
    Fady Kaldas
    Ronald W Busuttil
    Hepatobiliary & Pancreatic Diseases International, 2011, 10 (03) : 234 - 242
  • [3] Liver transplantation for hepatocellular carcinoma: an update
    Zarrinpar, Ali
    Kaldas, Fady
    Busuttil, Ronald W.
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2011, 10 (03) : 234 - 242
  • [4] Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update
    Kishore, Sirish A.
    Bajwa, Raazi
    Madoff, David C.
    CANCERS, 2020, 12 (04)
  • [5] Review on liver transplant for hepatocellular carcinoma
    Chiao, Hellen
    Yang, Chao-Hsiung Edward
    Frenette, Catherine T.
    TRANSLATIONAL CANCER RESEARCH, 2013, 2 (06) : 472 - 481
  • [6] New systemic agents for hepatocellular carcinoma: an update 2020
    von Felden, Johann
    CURRENT OPINION IN GASTROENTEROLOGY, 2020, 36 (03) : 177 - 183
  • [7] Sirolimus in Liver Transplant Recipients With Hepatocellular Carcinoma
    Grigg, Sam
    Gow, Paul
    Yeomans, Neville
    JOURNAL OF INVESTIGATIVE SURGERY, 2020, 33 (04) : 389 - 390
  • [8] LIVER TRANSPLANT ALLOCATION TO PATIENTS WITH HEPATOCELLULAR CARCINOMA
    Dawwas, Muhammad F.
    Watson, Christopher J.
    Gimson, Alexander E.
    HEPATOLOGY, 2008, 48 (04) : 351A - 351A
  • [9] Changes in Liver Transplant Criteria for Hepatocellular Carcinoma
    Dekey Lhewa
    Neehar D. Parikh
    Current Hepatology Reports, 2017, 16 (1) : 33 - 38
  • [10] Microvascular Invasion in Hepatocellular Carcinoma and Liver Transplant
    Jakhete, Neha
    Saberi, Behnam
    Jonassaint, Naudia L.
    Cosar, Arif M.
    Luu, Harry
    Kim, Amy
    Anders, Robert A.
    Philosophe, Benjamin
    Cameron, Andrew M.
    Gurakar, Ahmet
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2016, 14 : 14 - 18